DBPR108, A Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type 2 Diabetes Mellitus: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial of Single and Multiple Doses in Healthy Volunteers
1. Abstract 1.1. Aims DBPR108 is an orally active dipeptidyl peptidase 4 (DPP-4) inhibitor in animals. The present first-in-human randomized, double-blind, and placebo-controlled study evaluated DBPR108 for safety and tolerability in healthy adult Asian male volunteers. 1.2. Main Methods DBPR108 were orally given at 25-600 mg as single and multiple once-daily doses for 8 consecutive …